Alzheimer's and ABC transporters - new opportunities for diagnostics and treatment

Neurobiology of Disease

Volumn 72, Issue Part A, 2014, Pages 54-60

  Pahnke, Jens ^a,b   Langer, Oliver ^c,d   Krohn, Markus ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^c AIT AUSTRIAN INSTITUTE OF TECHNOLOGY   (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

ABC transporter; ABCA7; ABCB1; ABCC1; Alzheimer's disease; Amyloid beta; BBB; Blood brain barrier; Choroid plexus; Glymphatic system; Neurodegeneration; PET

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER A1; ABC TRANSPORTER A7; AMYLOID BETA PROTEIN; BEXAROTENE; BREAST CANCER RESISTANCE PROTEIN; DESMETHYLLOPERAMIDE C 11; EFAVIRENZ; HERBACEOUS AGENT; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PERFORIN; PIRENZEPINE; THIETHYLPERAZINE; TRACER; UNCLASSIFIED DRUG; VERAPAMIL C 11;

ALZHEIMER DISEASE; AMYLOID PLAQUE; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID; CHOROID PLEXUS; CLEARANCE; DEGENERATIVE DISEASE; EARLY DIAGNOSIS; GENETIC ASSOCIATION; GLYMPHATIC SYSTEM; HUMAN; MILD COGNITIVE IMPAIRMENT; MOLECULAR IMAGING; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERICYTE; PHAGOCYTOSIS; POSITRON EMISSION TOMOGRAPHY; REVIEW; SENILE PLAQUE; SINGLE NUCLEOTIDE POLYMORPHISM; VASCULAR AMYLOIDOSIS; ANIMAL; BRAIN; METABOLISM; MOUSE; SCINTISCANNING; VASCULARIZATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BLOOD-BRAIN BARRIER; BRAIN; CHOROID PLEXUS; HUMANS; MICE; POSITRON-EMISSION TOMOGRAPHY;

EID: 84909578898     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.04.001     Document Type: Review

References (118)

1. Abe-Dohmae S., et al. Human ABCA7 supports apolipoprotein-mediated release of cellular cholesterol and phospholipid to generate high density lipoprotein. J. Biol. Chem. 2004, 279:604-611.
2. Baello S., et al. TGF-beta1 regulation of multidrug resistance P-glycoprotein in the developing male blood-brain barrier. Endocrinology 2014, 155:475-484.
3. Bartels A.L., et al. Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA. J. Neural Transm. 2008, 115:1001-1009.
4. Bateman R.J., et al. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat. Med. 2006, 12:856-861.
5. Bauer B., et al. Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling. Mol. Pharmacol. 2008, 73:1444-1453.
6. 11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data. Clin. Pharmacol. Ther. 2012, 91:227-233.
7. Boche D., et al. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. Brain 2008, 131:3299-3310.
8. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. (Berl.) 1991, 82:239-259.
9. Braak H., et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24:197-211.
10. Brenn A., et al. Beta-amyloid downregulates MDR1-P-glycoprotein (Abcb1) expression at the blood-brain barrier in mice. Int. J. Alzheimers Dis. 2011, 2011:690121.
11. Brown M.A., et al. Crystal structure of BMP-9 and functional interactions with pro-region and receptors. J. Biol. Chem. 2005, 280:25111-25118.
12. Candela P., et al. Apical-to-basolateral transport of amyloid-beta peptides through blood-brain barrier cells is mediated by the receptor for advanced glycation end-products and is restricted by P-glycoprotein. J. Alzheimers Dis. 2010, 22:849-859.
13. Carrano A., et al. ATP-binding cassette transporters P-glycoprotein and breast cancer related protein are reduced in capillary cerebral amyloid angiopathy. Neurobiol. Aging 2014, 35:565-575.
14. Cascorbi I., et al. Association of ATP-binding cassette transporter variants with the risk of Alzheimer's disease. Pharmacogenomics 2013, 14:485-494.
15. Chikly B., Quaghebeur J. Reassessing cerebrospinal fluid (CSF) hydrodynamics: a literature review presenting a novel hypothesis for CSF physiology. J. Bodyw. Mov. Ther. 2013, 17:344-354.
16. Chung S.J., et al. Association of GWAS top hits with late-onset Alzheimer disease in Korean population. Alzheimer Dis. Assoc. Disord. 2013, 27:250-257.
17. Cirrito J.R., et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J. Clin. Invest. 2005, 115:3285-3290.
18. Cramer P.E., et al. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 2012, 335:1503-1506.
19. Damkier H.H., et al. Cerebrospinal fluid secretion by the choroid plexus. Physiol. Rev. 2013, 93:1847-1892.
20. Do T.M., et al. ABCG2- and ABCG4-mediated efflux of amyloid-beta peptide 1-40 at the mouse blood-brain barrier. J. Alzheimers Dis. 2012, 30:155-166.
21. Doody R.S., et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N. Engl. J. Med. 2013, 369:341-350.
22. Feher A., et al. Association between the ABCG2 C421A polymorphism and Alzheimer's disease. Neurosci. Lett. 2013, 550:51-54.
23. Fukumoto H., et al. Induction of the cholesterol transporter ABCA1 in central nervous system cells by liver X receptor agonists increases secreted Abeta levels. J. Biol. Chem. 2002, 277:48508-48513.
24. Funke C., et al. Genetic analysis of coding SNPs in blood-brain barrier transporter MDR1 in European Parkinson's disease patients. J. Neural Transm. 2009, 116:443-450.
25. Galante E., et al. Development of purine-derived (18)F-labeled pro-drug tracers for imaging of MRP1 activity with PET. J. Med. Chem. 2014, 57:1023-1032.
26. Gosselet F., et al. Transcriptional profiles of receptors and transporters involved in brain cholesterol homeostasis at the blood-brain barrier: use of an in vitro model. Brain Res. 2009, 1249:34-42.
27. Gosselet F., et al. Effects of oxysterols on the blood-brain barrier: implications for Alzheimer's disease. Biochem. Biophys. Res. Commun. 2013, (PMID: 24275140).
28. Gotzl J.K., et al. Common pathobiochemical hallmarks of progranulin-associated frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis. Acta Neuropathol. 2014, (PMID 24619111).
29. Gruber J., et al. Mitochondria-targeted antioxidants and metabolic modulators as pharmacological interventions to slow ageing. Biotechnol. Adv. 2013, 31:563-592.
30. Haass C., De Strooper B. The presenilins in Alzheimer's disease - proteolysis holds the key. Science 1999, 286:916-919.
31. Hardy J., Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. 1991, 12:383-388.
32. Hartz A.M., Bauer B. ABC transporters in the CNS - an inventory. Curr. Pharm. Biotechnol. 2011, 12:656-673.
33. Hartz A.M., et al. Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer's disease. Mol. Pharmacol. 2010, 77:715-723.
34. Hawkes C.A., et al. Regional differences in the morphological and functional effects of aging on cerebral basement membranes and perivascular drainage of amyloid-beta from the mouse brain. Aging Cell 2013, 12:224-236.
35. Hennings-Yeomans P.H., Cooper G.F. Improving the prediction of clinical outcomes from genomic data using multiresolution analysis. IEEE/ACM Trans. Comput. Biol. Bioinform. 2012, 9:1442-1450.
36. Hofrichter J., et al. Reduced Alzheimer's disease pathology by St. John's Wort treatment is independent of hyperforin and facilitated by ABCC1 and microglia activation in mice. Curr. Alzheimer Res. 2013, 10:1057-1069.
37. Hollingworth P., et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat. Genet. 2011, 43:429-435.
38. Holmes C., et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008, 372:216-223.
39. Holton P., et al. Initial assessment of the pathogenic mechanisms of the recently identified Alzheimer risk Loci. Ann. Hum. Genet. 2013, 77:85-105.
40. Iliff J.J., et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. Sci. Transl. Med. 2012, 4:147ra111.
41. Iliff J.J., et al. Brain-wide pathway for waste clearance captured by contrast-enhanced MRI. J. Clin. Invest. 2013, 123:1299-1309.
42. Iliff J.J., et al. Cerebral arterial pulsation drives paravascular CSF-interstitial fluid exchange in the murine brain. J. Neurosci. 2013, 33:18190-18199.
43. Jeynes B., Provias J. An investigation into the role of P-glycoprotein in Alzheimer's disease lesion pathogenesis. Neurosci. Lett. 2011, 487:389-393.
44. Juliano R.L., Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 1976, 455:152-162.
45. Kamboh M.I., et al. Genome-wide association study of Alzheimer's disease. Transl. Psychiatry 2012, 2:e117.
46. Kaminski W.E., et al. Identification of a novel human sterol-sensitive ATP-binding cassette transporter (ABCA7). Biochem. Biophys. Res. Commun. 2000, 273:532-538.
47. Kania K.D., et al. Beta amyloid effects on expression of multidrug efflux transporters in brain endothelial cells. Brain Res. 2011, 1418:1-11.
48. Kannan P., et al. Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin. Pharmacol. Ther. 2009, 86:368-377.
49. Karch C.M., et al. Expression of novel Alzheimer's disease risk genes in control and Alzheimer's disease brains. PLoS One 2012, 7:e50976.
50. Khoo S.K., et al. Host response transcriptional profiling reveals extracellular components and ABC (ATP-binding cassette) transporters gene enrichment in typhoid fever-infected Nigerian children. BMC Infect. Dis. 2011, 11:241.
51. Kim W.S., et al. Abca7 null mice retain normal macrophage phosphatidylcholine and cholesterol efflux activity despite alterations in adipose mass and serum cholesterol levels. J. Biol. Chem. 2005, 280:3989-3995.
52. Kim W.S., et al. Role of ATP-binding cassette transporters in brain lipid transport and neurological disease. J. Neurochem. 2008, 104:1145-1166.
53. Kim S., et al. Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort. Neurology 2011, 76:69-79.
54. Kim W.S., et al. Deletion of Abca7 increases cerebral amyloid-beta accumulation in the J20 mouse model of Alzheimer's disease. J. Neurosci. 2013, 33:4387-4394.
55. Kiyohara C., et al. MDR1 C3435T polymorphism and interaction with environmental factors in risk of Parkinson's disease: a case-control study in Japan. Drug Metab. Pharmacokinet. 2013, 28:138-143.
56. Ko K.M., Leung H.Y. Enhancement of ATP generation capacity, antioxidant activity and immunomodulatory activities by Chinese Yang and Yin tonifying herbs. Chin. Med. 2007, 2:3.
57. Krohn M., et al. Cerebral amyloid-beta proteostasis is regulated by the membrane transport protein ABCC1 in mice. J. Clin. Invest. 2011, 121:3924-3931.
58. Kubo Y., et al. ABCA5 resides in lysosomes, and ABCA5 knockout mice develop lysosomal disease-like symptoms. Mol. Cell. Biol. 2005, 25:4138-4149.
59. Kuhnke D., et al. MDR1-P-glycoprotein (ABCB1) mediates transport of Alzheimer's amyloid-beta peptides - implications for the mechanisms of Abeta clearance at the blood-brain barrier. Brain Pathol. 2007, 17:347-353.
60. Lam F.C., et al. beta-Amyloid efflux mediated by p-glycoprotein. J. Neurochem. 2001, 76:1121-1128.
61. Lehtinen M.K., et al. The choroid plexus and cerebrospinal fluid: emerging roles in development, disease, and therapy. J. Neurosci. 2013, 33:17553-17559.
62. Lemmen J., et al. Pregnane X receptor upregulates ABC-transporter Abcg2 and Abcb1 at the blood-brain barrier. Brain Res. 2013, 1491:1-13.
63. Linton K.J. Structure and function of ABC transporters. Physiology (Bethesda) 2007, 22:122-130.
64. Liu L.H., et al. A complex association of ABCA7 genotypes with sporadic Alzheimer disease in Chinese Han population. Alzheimer Dis. Assoc. Disord. 2013, (PMID 24113560).
65. Löscher W., Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat. Rev. Neurosci. 2005, 6:591-602.
66. Maia L., de Mendonca A. Does caffeine intake protect from Alzheimer's disease?. Eur. J. Neurol. 2002, 9:377-382.
67. Mairinger S., et al. PET and SPECT radiotracers to assess function and expression of ABC transporters in vivo. Curr. Drug Metab. 2011, 12:774-792.
68. Mapstone M., et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat. Med. 2014, 20:415-418. (PMID: 24608097).
69. Meurs I., et al. Effects of deletion of macrophage ABCA7 on lipid metabolism and the development of atherosclerosis in the presence and absence of ABCA1. PLoS One 2012, 7:e30984.
70. Meyer E.P., et al. Altered morphology and 3D architecture of brain vasculature in a mouse model for Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:3587-3592.
71. Mosconi L., et al. Maternal transmission of Alzheimer's disease: prodromal metabolic phenotype and the search for genes. Hum. Genomics 2010, 4:170-193.
72. 11C-verapamil in the brain: studies of healthy humans. J. Nucl. Med. 2009, 50:1267-1275.
73. Nazer B., et al. LRP promotes endocytosis and degradation, but not transcytosis, of the amyloid-beta peptide in a blood-brain barrier in vitro model. Neurobiol. Dis. 2008, 30:94-102.
74. Obermeier B., et al. Development, maintenance and disruption of the blood-brain barrier. Nat. Med. 2013, 19:1584-1596.
75. Okamura T., et al. Noninvasive and quantitative assessment of the function of multidrug resistance-associated protein 1 in the living brain. J. Cereb. Blood Flow Metab. 2009, 29:504-511.
76. Paganetti P., et al. Increased efflux of amyloid-beta peptides through the blood-brain barrier by muscarinic acetylcholine receptor inhibition reduces pathological phenotypes in mouse models of brain amyloidosis. J. Alzheimers Dis. 2014, 38:767-786.
77. Pahnke J., et al. Clinico-pathologic function of cerebral ABC transporters - implications for the pathogenesis of Alzheimer's disease. Curr. Alzheimer Res. 2008, 5:396-405.
78. Pahnke J., et al. Alzheimer's disease and blood-brain barrier function - why have anti-beta-amyloid therapies failed to prevent dementia progression?. Neurosci. Biobehav. Rev. 2009, 33:1099-1108.
79. Papadopoulos M.C., Verkman A.S. Aquaporin water channels in the nervous system. Nat. Rev. Neurosci. 2013, 14:265-277.
80. Pflanzner T., et al. LRP1 mediates bidirectional transcytosis of amyloid-beta across the blood-brain barrier. Neurobiol. Aging 2011, 32(2323):e1-e11.
81. Pflanzner T., et al. Cellular prion protein participates in amyloid-beta transcytosis across the blood-brain barrier. J. Cereb. Blood Flow Metab. 2012, 32:628-632.
82. Pollock H., et al. Perivascular spaces in the basal ganglia of the human brain: their relationship to lacunes. J. Anat. 1997, 191(Pt 3):337-346.
83. Qosa H., et al. Enhanced brain amyloid-beta clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer's disease. J. Alzheimers Dis. 2012, 31:151-165.
84. Qosa H., et al. Differences in amyloid-beta clearance across mouse and human blood-brain barrier models: kinetic analysis and mechanistic modeling. Neuropharmacology 2014, 79:668-678.
85. Rajagopal A., Simon S.M. Subcellular localization and activity of multidrug resistance proteins. Mol. Biol. Cell 2003, 14:3389-3399.
86. Reitz C., et al. Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E 4, and the risk of late-onset Alzheimer disease in African Americans. JAMA 2013, 309:1483-1492.
87. Ritchie K., et al. The neuroprotective effects of caffeine: a prospective population study (the Three City Study). Neurology 2007, 69:536-545.
88. Saint-Pol J., et al. Oxysterols decrease apical-to-basolateral transport of Ass peptides via an ABCB1-mediated process in an in vitro blood-brain barrier model constituted of bovine brain capillary endothelial cells. Brain Res. 2013, 1517:1-15.
89. Savica R., et al. Incidence of dementia with Lewy bodies and Parkinson disease dementia. JAMA Neurol. 2013, 70:1396-1402.
90. Scheffler K., et al. Mitochondrial DNA polymorphisms specifically modify cerebral beta-amyloid proteostasis. Acta Neuropathol. 2012, 124:199-208.
91. Schinkel A.H., Jonker J.W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv. Drug Deliv. Rev. 2003, 55:3-29.
92. Schley D., et al. Mechanisms to explain the reverse perivascular transport of solutes out of the brain. J. Theor. Biol. 2006, 238:962-974.
93. Schumacher T., et al. ABC transporters B1, C1 and G2 differentially regulate neuroregeneration in mice. PLoS One 2012, 7:e35613.
94. Serot J.M., et al. Choroid plexus, aging of the brain, and Alzheimer's disease. Front. Biosci. 2003, 8:s515-s521.
95. Shen S., et al. ABCG2 reduces ROS-mediated toxicity and inflammation: a potential role in Alzheimer's disease. J. Neurochem. 2010, 114:1590-1604.
96. Szakacs G., et al. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 2006, 5:219-234.
97. Tai L.M., et al. P-glycoprotein and breast cancer resistance protein restrict apical-to-basolateral permeability of human brain endothelium to amyloid-beta. J. Cereb. Blood Flow Metab. 2009, 29:1079-1083.
98. Tan E.K., et al. Effect of MDR1 haplotype on risk of Parkinson disease. Arch. Neurol. 2005, 62:460-464.
99. Tanaka N., et al. Helical apolipoproteins of high-density lipoprotein enhance phagocytosis by stabilizing ATP-binding cassette transporter A7. J. Lipid Res. 2010, 51:2591-2599.
100. Tanaka N., et al. HMG-CoA reductase inhibitors enhance phagocytosis by upregulating ATP-binding cassette transporter A7. Atherosclerosis 2011, 217:407-414.
101. Tecedor L., et al. CLN3 loss disturbs membrane microdomain properties and protein transport in brain endothelial cells. J. Neurosci. 2013, 33:18065-18079.
102. Tsutsumi S., et al. The Virchow-Robin spaces: delineation by magnetic resonance imaging with considerations on anatomofunctional implications. Childs Nerv. Syst. 2011, 27:2057-2066.
103. van Assema D.M., et al. Blood-brain barrier P-glycoprotein function in Alzheimer's disease. Brain 2012, 135:181-189.
104. van Assema D.M., et al. Blood-brain barrier P-glycoprotein function in healthy subjects and Alzheimer's disease patients: effect of polymorphisms in the ABCB1 gene. EJNMMI Res. 2012, 2:57.
105. van Gelder B.M., et al. Coffee consumption is inversely associated with cognitive decline in elderly European men: the FINE Study. Eur. J. Clin. Nutr. 2007, 61:226-232.
106. Vann Jones S.A., O'Brien J.T. The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol. Med. 2014, 44:673-683.
107. Vardarajan B.N., et al. Age-specific incidence rates for dementia and Alzheimer disease in NIA-LOAD/NCRAD and EFIGA families: National Institute on Aging Genetics Initiative for Late-Onset Alzheimer Disease/National Cell Repository for Alzheimer Disease (NIA-LOAD/NCRAD) and Estudio Familiar de Influencia Genetica en Alzheimer (EFIGA). JAMA Neurol. 2014, 71:315-323.
108. Vasquez J.B., et al. ABCA7 expression is associated with Alzheimer's disease polymorphism and disease status. Neurosci. Lett. 2013, 556:58-62.
109. Verhaaren B.F., et al. Alzheimer's disease genes and cognition in the nondemented general population. Biol. Psychiatry 2013, 73:429-434.
110. Vogelgesang S., et al. Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 2002, 12:535-541.
111. Vogelgesang S., et al. The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease. Curr Alzheimer Res. 2004, 1:121-125.
112. Weller R.O., et al. Pathways of fluid drainage from the brain - morphological aspects and immunological significance in rat and man. Brain Pathol. 1992, 2:277-284.
113. Weller R.O., et al. Microvasculature changes and cerebral amyloid angiopathy in Alzheimer's disease and their potential impact on therapy. Acta Neuropathol. 2009, 118:87-102.
114. Westerlund M., et al. Association of a polymorphism in the ABCB1 gene with Parkinson's disease. Parkinsonism Relat. Disord. 2009, 15:422-424.
115. Xiong H., et al. ABCG2 is upregulated in Alzheimer's brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for Abeta(1-40) peptides. J. Neurosci. 2009, 29:5463-5475.
116. Zhang E.T., et al. Interrelationships of the pia mater and the perivascular (Virchow-Robin) spaces in the human cerebrum. J. Anat. 1990, 170:111-123.
117. Zhou C., et al. Atp-binding cassette transporter ABC2/ABCA2 in the rat brain: a novel mammalian lysosome-associated membrane protein and a specific marker for oligodendrocytes but not for myelin sheaths. J. Neurosci. 2001, 21:849-857.
118. Zschiedrich K., et al. MDR1 variants and risk of Parkinson disease. Association with pesticide exposure?. J. Neurol. 2009, 256:115-120.